211 related articles for article (PubMed ID: 33574356)
1. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met.
Damghani T; Moosavi F; Khoshneviszadeh M; Mortazavi M; Pirhadi S; Kayani Z; Saso L; Edraki N; Firuzi O
Sci Rep; 2021 Feb; 11(1):3644. PubMed ID: 33574356
[TBL] [Abstract][Full Text] [Related]
2. Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library.
Mortazavi M; Raufi E; Damghani T; Khoshneviszadeh M; Edraki N; Eskandari M; Giovannetti E; Peters GJ; Pirhadi S; Firuzi O
Eur J Pharmacol; 2023 Jan; 938():175395. PubMed ID: 36410418
[TBL] [Abstract][Full Text] [Related]
3. Novel quinazoline-1,2,3-triazole hybrids with anticancer and MET kinase targeting properties.
Mortazavi M; Eskandari M; Moosavi F; Damghani T; Khoshneviszadeh M; Pirhadi S; Saso L; Edraki N; Firuzi O
Sci Rep; 2023 Sep; 13(1):14685. PubMed ID: 37673888
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effect, alteration of cancer cell cycle progression and potential MET kinase inhibition induced by 3,4-dihydropyrimidin-2(1H)-one C5 amide derivatives.
Moosavi F; Ebadi A; Mohabbati M; Damghani T; Mortazavi M; Miri R; Firuzi O
Eur J Pharmacol; 2021 Mar; 894():173850. PubMed ID: 33428899
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
[TBL] [Abstract][Full Text] [Related]
6. Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
Yang Y; Zhang Y; Yang L; Zhao L; Si L; Zhang H; Liu Q; Zhou J
Bioorg Chem; 2017 Feb; 70():126-132. PubMed ID: 28043720
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
Liu TC; Peng X; Ma YC; Ji YC; Chen DQ; Zheng MY; Zhao DM; Cheng MS; Geng MY; Shen JK; Ai J; Xiong B
Acta Pharmacol Sin; 2016 May; 37(5):698-707. PubMed ID: 27041462
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Anti-Proliferative Evaluations of New Heterocyclic Derivatives Using 5,6,8,9-Tetrahydropyrazolo[5,1-b]quinazolin-7(3H)-one Derivatives Derived from Cyclohexa-1,4-dione.
Mahmoud MAA; Alsharif MA; Mohareb RM
Anticancer Agents Med Chem; 2021; 21(4):468-486. PubMed ID: 32445457
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
An XD; Liu H; Xu ZL; Jin Y; Peng X; Yao YM; Geng M; Long YQ
Bioorg Med Chem Lett; 2015 Feb; 25(3):708-16. PubMed ID: 25529740
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors.
Gu W; Dai Y; Qiang H; Shi W; Liao C; Zhao F; Huang W; Qian H
Bioorg Chem; 2017 Jun; 72():116-122. PubMed ID: 28411406
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Tang Q; Wang L; Tu Y; Zhu W; Luo R; Tu Q; Wang P; Wu C; Gong P; Zheng P
Bioorg Med Chem Lett; 2016 Apr; 26(7):1680-4. PubMed ID: 26923692
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer.
Yan HH; Jung KH; Son MK; Fang Z; Kim SJ; Ryu YL; Kim J; Kim MH; Hong SS
Oncotarget; 2014 Oct; 5(19):9150-68. PubMed ID: 25193856
[TBL] [Abstract][Full Text] [Related]
16. 1,2,4-Oxadiazole Topsentin Analogs with Antiproliferative Activity against Pancreatic Cancer Cells, Targeting GSK3β Kinase.
Carbone D; Parrino B; Cascioferro S; Pecoraro C; Giovannetti E; Di Sarno V; Musella S; Auriemma G; Cirrincione G; Diana P
ChemMedChem; 2021 Feb; 16(3):537-554. PubMed ID: 33141472
[TBL] [Abstract][Full Text] [Related]
17. Prediction of cytotoxic activity of a series of 1H-pyrrolo[2,3-b]pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints.
Damghani T; Mashayekh K; Pirhadi S; Firuzi O; Sharifi S; Edraki N; Khoshneviszadeh M; Avestan MS
J Recept Signal Transduct Res; 2019 Aug; 39(4):295-303. PubMed ID: 31658862
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
Liu M; Hou Y; Yin W; Zhou S; Qian P; Guo Z; Xu L; Zhao Y
Eur J Med Chem; 2016 Aug; 119():96-108. PubMed ID: 27155466
[TBL] [Abstract][Full Text] [Related]
19. Phytochemicals, withaferin A and carnosol, overcome pancreatic cancer stem cells as c-Met inhibitors.
Aliebrahimi S; Kouhsari SM; Arab SS; Shadboorestan A; Ostad SN
Biomed Pharmacother; 2018 Oct; 106():1527-1536. PubMed ID: 30119228
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
